Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9755705 | 0.77 | ESR1 (0.47) | HTR2AHTR2CALDH1A1ESR1ESR2 | |
| SCHEMBL17548554 | 0.75 | ALDH1A1 (0.43) | HTR2AHTR2CALDH1A1 | |
| SCHEMBL7915425 | 0.73 | ESR1 (0.53) | HTR2AHTR2CALDH1A1SMN1; SMN2ESR1 | |
| SCHEMBL13024122 | 0.71 | ESR1 (0.60) | HTR2AHTR2CDRD2ALDH1A1ESR1 | |
| SCHEMBL4884271 | 0.68 | ESR1 (0.55) | HTR2AHTR2CALDH1A1ESR1ESR2 | |
| SCHEMBL11495830 | 0.67 | HTR2A (0.71) | HTR2AHTR2CDRD2ESR1ESR2 | |
| SCHEMBL28906358 | 0.66 | ESR1 (0.57) | HTR2AHTR2CDRD2ALDH1A1ESR1 | |
| Water SCHEMBL11573403 | 0.65 | SMN1; SMN2 (0.50) | HTR2AHTR2CDRD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7646413 | 0.65 | HTR2A (1.00) | HTR2AHTR2CDRD2HTR6 | |
| SCHEMBL7276308 | 0.64 | HTR2A (0.57) | HTR2AHTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2019-08-13 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016029310-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | HTR2A 50/4885HTR2C 37/4885DRD2 287/4885 |
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | CNR1, CNR2, GPR18 | HTR2A 50/4885HTR2C 37/4885DRD2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.